Navigation Links
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
Date:7/26/2010

linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='99222084';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.onyx-pharm.com/view.cfm/32/Event-Calendar">http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-619-6547 and using the passcode 27571112.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 27571112# approximately one hour after the teleconference concludes.  The replay will be available through August 9, 2010. 

About the Carfilzomib Development Program

Carfilzomib is a selective, next-generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma.

As previously reported at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, an ongoing, companion Phase 2 study, known as the 004 study, demonstrated encouraging overall response rates, tolerability and durable disease control when carfilzomib was administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.  In 53 evaluable patients who had not been previously treated with bortezomib, carfilzomib achieved an overall response rate of 55 percent and a median duration of response of 11.5 months at 27mg/m2.  Forty percent of patients were refractory to their most recent therapy prior to entering the trial.  In the overall 004 study population, treatment with carfilzomib was well-tolerated, and no new or unexpected adverse events occurred. The most common Grade 3 treatment-emergent adverse events included: pneumonia (11 percent), anemia (9.7 percent), neutropenia (9.7 percent) and thrombocytopenia (9 percent). Peripheral neuropathy of any grade was infrequent, and no Grade 4 adverse
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
2. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
5. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
6. Lotus Pharmaceuticals Terminates SEDA
7. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
8. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
9. Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010
10. Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector
11. Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... SANTA MONICA, Calif. , July 29, 2015 /PRNewswire/ ... to the San Diego Marriott Marquis & Marina on ... the medical device industry. A highlight of the Business ... Secure Financial Backing from Different Types of Investors, featuring ... Johnson & Johnson Development Corporation; Brent Ahrens , ...
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... Angeles, California (PRWEB) , ... July 30, 2015 , ... ... August 5th 2015 - “Learn How to Make Money in the Booming Homecare Business.” ... Los Angeles CA 90010. , The event will be hosted by ...
(Date:7/30/2015)... ... 2015 , ... After conducting a nationwide executive search led by healthcare leadership ... Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed ... leadership experience, Walsh is an expert in organizational change, physician development, implementation of quality ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... with its Medicare administrative contractor (MAC) over submitted claims for bariatric surgery that, ... a challenge to program integrity, Becky Dennis, a nurse auditor at WellSpan Health, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... largest amount of research grants in its history of funding brain aneurysm research. ... who have dedicated their life’s work toward scientific research directed at early detection, ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4
... drugs meant for treating HIV patients also served to protect ... the same can be applied to human beings also has ... ,Rhesus monkeys were experimented upon by the ... them with a version of the Truvada, manufactured by Gilead ...
... older adults due to brain related changes, according to ... easy where younger adults are concerned. The healthy middle ... good where concentrating is concerned, according to functional magnetic ... of the Rotman Research Institute at the Baycrest Center ...
... rates of patients, specific for every surgeon in Scotland has ... community. A majority of the surgeons feel that the ... the surgeon, list of hospitals in which the surgeon has ... the associated mortality rate are amongst the details published. The ...
... that there has been an increase in heart failure cases among ... with men surviving for longer periods. There has been a ... to 1994 period when compared to the 1970 to 1974 period, ... the study. ,The chances of heart failure occurring ...
... National Institute of Immunology are reported to have identified ... the tuberculosis (TB) bacteria survives in the human body. ... more effective medicines to combat the disease, which claims ... annually. The research team led by Rajesh S. Gokhale ...
... A team of researchers led by Dr Stephen Harbarth have ... to be useful in reducing the // infection rates ... by the NHS in dealing with the bug. ... in patient swabs. The researchers said that this test was ...
Cached Medicine News:Health News:The Publication Of Surgeon Specific Death Rates Raises Controversy 2
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: